Harrow (HROW) Other Non-Current Assets (2017 - 2021)
Harrow's (HROW) quarterly Other Non-Current Assets came in at $200000.0 in Q3 2021, little changed year-on-year from $200000.0 in Q3 2020, and little changed quarter-over-quarter from $200000.0 in Q2 2021.
Harrow (HROW) Other Non-Current Assets (2017 - 2021) Analysis & Trends
Harrow's Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $200000.0 for Q3 2021.
- On a quarterly basis, Other Non-Current Assets changed 0.0% year-over-year to $200000.0 in Q3 2021; TTM through Sep 2021 was $200000.0, a 0.0% change from a year earlier, with the FY2020 full-year figure at $200000.0, changed 0.0% from the prior year.
- Other Non-Current Assets steadied at $200000.0 in Q3 2021 per HROW's latest filing, from $200000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $631000.0 in Q2 2017 and bottomed at $200000.0 in Q4 2017.
- The 5-year median for Other Non-Current Assets is $200000.0 (2017), against an average of $247888.9.
- Biggest YoY gain for Other Non-Current Assets was 0.0% in 2018; the steepest drop was 68.3% in 2018.
- Year by year, Other Non-Current Assets stood at $200000.0 in 2017, then changed by 0.0% to $200000.0 in 2018, then changed by 0.0% to $200000.0 in 2019, then changed by 0.0% to $200000.0 in 2020, then changed by 0.0% to $200000.0 in 2021.
- Per Business Quant, the three latest HROW Other Non-Current Assets figures stand at $200000.0 (Q3 2021), $200000.0 (Q2 2021), and $200000.0 (Q1 2021).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 200,000.00 |
| Jun 30, 2021 | 200,000.00 |
| Mar 31, 2021 | 200,000.00 |
| Dec 31, 2020 | 200,000.00 |
| Sep 30, 2020 | 200,000.00 |
| Jun 30, 2020 | 200,000.00 |
| Mar 31, 2020 | 200,000.00 |
| Dec 31, 2019 | 200,000.00 |
| Sep 30, 2019 | 200,000.00 |
| Jun 30, 2019 | 200,000.00 |
| Mar 31, 2019 | 200,000.00 |
| Dec 31, 2018 | 200,000.00 |
| Sep 30, 2018 | 200,000.00 |
| Jun 30, 2018 | 200,000.00 |
| Mar 31, 2018 | 200,000.00 |
| Dec 31, 2017 | 200,000.00 |
| Sep 30, 2017 | 631,000.00 |
| Jun 30, 2017 | 631,000.00 |